Payment overview · 2025
General Payments
$3,786.96
100 reported records · 24 companies
Healthcare provider profile · identity verified
Vivek V Kumar, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · LAKEWOOD RANCH, FL · NPI 1508814906
Verified facts
What the public records show
CMS Open Payments records show Vivek V Kumar, D.O. received $3,786.96 in general payments during 2025 across 100 reported records.
Boston Scientific Corporation accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,265.43 | 33.4% | 18 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $602.04 | 15.9% | 11 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $280.12 | 7.4% | 6 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $268.80 | 7.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$194.67 | 5.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.05 | 3.6% | 9 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $135.56 | 3.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.65 | 2.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.87 | 2.4% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $85.46 | 2.3% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.66 | 2.2% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $80.94 | 2.1% | 5 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $70.00 | 1.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.25 | 1.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $58.54 | 1.6% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $46.77 | 1.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $45.39 | 1.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $40.33 | 1.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $32.17 | 0.8% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $28.49 | 0.8% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $27.21 | 0.7% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $24.35 | 0.6% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $18.20 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.01 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,737.52 | 92 |
| Travel and Lodging | $950.44 | 7 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $588.65 | 10 | 2025 |
Source payment records
|
|||||
| INGEVITY MRI Normalized: ingevity mri |
Device | Boston Scientific Corporation | $416.64 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $375.95 | 4 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $343.17 | 6 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $195.77 | 7 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $195.77 | 7 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $148.73 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $135.56 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $110.55 | 8 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $108.70 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $99.33 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $99.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.87 | 6 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $83.66 | 3 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $70.00 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $45.94 | 3 | 2025 |
Source payment records
|
|||||
| Event Normalized: event |
Device | Philips North America LLC | $44.63 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $40.83 | 2 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $38.20 | 1 | 2025 |
Source payment records
|
|||||
| S-ICD System Magnet Normalized: s icd system magnet |
Device | Boston Scientific Corporation | $37.99 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $33.67 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $32.17 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $25.00 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $22.28 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $13.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 299 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 105 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
299 | 78 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
105 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
299 | 78 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 620 | 214 |
| Clopidogrel | Clopidogrel Bisulfate | 323 | 113 |
| Eliquis | Apixaban | 299 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 235 | 81 |
| Losartan Potassium | Losartan Potassium | 163 | 57 |
| Valsartan | Valsartan | 157 | 57 |
| Carvedilol | Carvedilol | 156 | 46 |
| Lisinopril | Lisinopril | 144 | 54 |
| Flecainide Acetate | Flecainide Acetate | 137 | 36 |
| Xarelto | Rivaroxaban | 130 | 41 |
| Entresto | Sacubitril/Valsartan | 105 | 31 |
| Potassium Chloride | Potassium Chloride | 104 | 33 |
| Ezetimibe | Ezetimibe | 96 | 34 |
| Ranolazine Er | Ranolazine | 95 | 31 |
| Furosemide | Furosemide | 89 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 21 |
| Repatha Sureclick | Evolocumab | 68 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 11 |
| Nitroglycerin | Nitroglycerin | 43 | 27 |
| Simvastatin | Simvastatin | 39 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 18 |
| Spironolactone | Spironolactone | 38 | 16 |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 34 | 11 |
| Amoxicillin | Amoxicillin | 33 | 18 |
| Torsemide | Torsemide | 32 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,786.96 · 100 records | Boston Scientific Corporation | AREXVY, ASSURITY, AURYON LASER SYSTEM 100-120 VAC, AVEIR, AZURE XT DR MRI SURESCAN, Attruby, Barostim Neo System, CAMZYOS, CDS - MCT/CEM Monitoring, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, ENTRESTO, Event, Extended Holter, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, FUROSCIX, General - Brady, General - CRM_CRM, General - Tachy, HAWKONE, INGEVITY MRI, INGEVITY+, Indigo System, JARDIANCE, LEQVIO, LifeVest, ONPATTRO, OPSUMIT, Penumbra System, REPATHA, S-ICD System Magnet, SHINGRIX, UPTRAVI, VERQUVO, VYNDAQEL, WINREVAIR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error